Antonella Dal Cin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonella Dal Cin has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Guzzinati
Epidemiological Department, Azienda Zero, Padova, Italy
3 shared publications - Alberto Bosio
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy
2 shared publications - Alessandra Andreotti
Veneto Cancer Registry, Epidemiological Department, Azienda Zero, 35132 Padua, Italy
2 shared publications - Alessandra Greco
Veneto Cancer Registry, Epidemiological Department, Azienda Zero, 35132 Padua, Italy
2 shared publications - Anna Rita Fiore
Veneto Cancer Registry, Epidemiological Department, Azienda Zero, 35132 Padua, Italy
2 shared publications - Carmen Stocco
Veneto Cancer Registry, Epidemiological Department, Azienda Zero, 35132 Padua, Italy
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 236
Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one-third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.
- 21 April 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 236
Open AccessReal-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one-third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.
- Open Access
- 16 March 2026
- Published by MDPI AG in Preprints.org
Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1,634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.
- 16 March 2026
- Published by MDPI AG in Preprints.org
Open AccessReal-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1,634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.
- Open Access
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (9) , 1224-1232
Indicators of cure for women living after uterine and ovarian cancers: a population-based study
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate net survival, cure fraction, time to cure (when 5-year conditional net survival becomes > 95%), cure prevalence (women who will not die of cancer), and already cured (living longer than time to cure). In 2018, 0.4% (121 704) of Italian women were alive after diagnosis of corpus uteri cancer, 0.2% (52 551) after cervical cancer, and 0.2% (52 153) after ovarian cancer. More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die from their neoplasm (cure prevalence). Women with gynecological cancers have a residual excess risk of death This article is part of a Special Collection on Gynecological Cancers.
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (9) , 1224-1232
Open AccessIndicators of cure for women living after uterine and ovarian cancers: a population-based study
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate net survival, cure fraction, time to cure (when 5-year conditional net survival becomes > 95%), cure prevalence (women who will not die of cancer), and already cured (living longer than time to cure). In 2018, 0.4% (121 704) of Italian women were alive after diagnosis of corpus uteri cancer, 0.2% (52 551) after cervical cancer, and 0.2% (52 153) after ovarian cancer. More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die from their neoplasm (cure prevalence). Women with gynecological cancers have a residual excess risk of death This article is part of a Special Collection on Gynecological Cancers.